医学
子痫前期
阿司匹林
产科
怀孕
妊娠期
人口
胎龄
儿科
内科学
环境卫生
遗传学
生物
作者
US Preventive Services Task Force,Karina W. Davidson,Michael J. Barry,Carol M. Mangione,Michael D. Cabana,Aaron B. Caughey,Esa M. Davis,Katrina E Donahue,Chyke A. Doubeni,Martha Kubik,Li Li,Gbenga Ogedegbe,Lori Pbert,Michael Silverstein,Melissa A. Simon,James J. Stevermer,Chien-Wen Tseng,John B. Wong
出处
期刊:JAMA
[American Medical Association]
日期:2021-09-28
卷期号:326 (12): 1186-1186
被引量:162
标识
DOI:10.1001/jama.2021.14781
摘要
Importance
Preeclampsia is one of the most serious health problems that affect pregnant persons. It is a complication in approximately 4% of pregnancies in the US and contributes to both maternal and infant morbidity and mortality. Preeclampsia also accounts for 6% of preterm births and 19% of medically indicated preterm births in the US. There are racial and ethnic disparities in the prevalence of and mortality from preeclampsia. Non-Hispanic Black women are at greater risk for developing preeclampsia than other women and experience higher rates of maternal and infant morbidity and perinatal mortality. Objective
To update its 2014 recommendation, the USPSTF commissioned a systematic review to evaluate the effectiveness of low-dose aspirin use to prevent preeclampsia. Population
Pregnant persons at high risk for preeclampsia who have no prior adverse effects with or contraindications to low-dose aspirin. Evidence Assessment
The USPSTF concludes with moderate certainty that there is a substantial net benefit of daily low-dose aspirin use to reduce the risk for preeclampsia, preterm birth, small for gestational age/intrauterine growth restriction, and perinatal mortality in pregnant persons at high risk for preeclampsia. Recommendation
The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication for preeclampsia after 12 weeks of gestation in persons who are at high risk for preeclampsia. (B recommendation)
科研通智能强力驱动
Strongly Powered by AbleSci AI